A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) (NCT06808477)
A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Who can join: Review the eligibility criteria below.
Location: First OC Dermatology — Irvine, California
Age range: 18 Years to 72 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- First OC Dermatology — Irvine, California
- OptiSkin Medical — New York, New York
- Equity Medical, LLC — The Bronx, New York
- Fremantle Dermatology — Fremantle, Western Australia
- Linear Clinical Research — Perth, Western Australia
- Optimal Clinical Trials Central Auckland — Grafton, Auckland
- Aotearoa Clinical Trials — Otahuhu, Auckland
- Pacific Clinical Research Network (PCRN) - Auckland — Takapuna, Auckland
- Optimal Clinical Trials Ltd - Christchurch — Christchurch,
- Pacific Clinical Research Network (PCRN) Wellington — Upper Hutt,
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi — Lodz,
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie — Rzeszów,
- Państwowy Instytut Medyczny MSWiA — Warsaw,
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska — Wroclaw,
📞 Contact the Study Coordinator
Phone: (617) 848-6188
Email: Lisa.Li@bambusatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.